SALT
LAKE CITY, July 25, 2024 /PRNewswire/ --
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics
company with a unique, patented platform for the development of
molecular diagnostic tests, announced today it will release its
second quarter 2024 results on Thursday,
August 8, 2024, after the market close. The Company will
also host a conference call and webcast on the same day at
4:30 p.m. ET to discuss its financial
results with analysts and institutional investors. Management on
the call will include Dwight Egan,
Chief Executive Officer, Brian
Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
The conference call and webcast will be available via:
Webcast: ir.codiagnostics.com on the Events & Webcasts
page
Conference Call: 844-481-2661 (domestic) or 412-317-0652
(international)
If you are unable to participate during the live webcast, the
call will be recorded and later made available on the Company's
website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and to
locate genetic markers for use in applications other than
infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-second-quarter-2024-earnings-release-date-and-webcast-302206409.html
SOURCE Co-Diagnostics
